Brought to you by 
Newly formed Mirrx gets undisclosed amount in seed round
06 May 2022
Executive Summary
Concurrent with its spin off from Stealth Biotech, antisense company Mirrx Therapeutics has raised an undisclosed amount in its seed financing from Seed Capital, Inventure Capital, and Vecata Invest.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Newly formed Mirrx gets undisclosed amount in seed round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice